CD4 and inflammatory bowel disease: While the results of this cohort study cannot be used to direct clinical practice without further validation, our data support the hypothesis that TcdB-specific CD4+ T cell responses might be useful in identifying IBD patients who would benefit from microbiome-based therapeutics to reduce C. difficile vegetative growth and toxin production.